Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $17.57 USD
Change Today +0.49 / 2.87%
Volume 2.0M
MNTA On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

momenta pharmaceuticals inc (MNTA) Snapshot

Open
$17.46
Previous Close
$17.08
Day High
$18.48
Day Low
$17.30
52 Week High
04/16/15 - $20.43
52 Week Low
10/13/14 - $9.38
Market Cap
1.0B
Average Volume 10 Days
1.6M
EPS TTM
$-1.91
Shares Outstanding
57.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MOMENTA PHARMACEUTICALS INC (MNTA)

momenta pharmaceuticals inc (MNTA) Related Businessweek News

No Related Businessweek News Found

momenta pharmaceuticals inc (MNTA) Details

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases. The company’s complex generics programs comprise Enoxaparin sodium injection, a generic version of Lovenox that is used for the prevention and treatment of deep vein thrombosis, and to support the treatment of acute coronary syndromes; and M356, a generic version of Copaxone, which is a complex drug consisting of a synthetic mixture of polypeptide chains for the treatment of patients with relapsing-remitting multiple sclerosis. Its biosimilars programs include M923, a biosimilar for rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis; M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis; and other biosimilar programs. The company’s novel products comprise M402, a novel oncology drug candidate that is in a Phase 2 clinical study derived from heparin; hsIVIg program, a hyper-sialylated version of intravenous immunoglobulin; SIF3 program, a novel recombinant protein containing three IgG Fc regions joined to maximize activity; and Anti-FcRn program for acute and chronic/intermittent therapies in a range of autoantibody driven diseases. It has collaboration and license agreements with Sandoz AG; Baxter International, Inc.; Baxter Healthcare Corporation; and Baxter Healthcare SA. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.

256 Employees
Last Reported Date: 02/27/15
Founded in 2001

momenta pharmaceuticals inc (MNTA) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $621.0K
Co-Founder, Chief Scientific Officer and Seni...
Total Annual Compensation: $387.5K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $362.5K
Senior Vice President and President of Biosim...
Total Annual Compensation: $19.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $395.7K
Compensation as of Fiscal Year 2013.

momenta pharmaceuticals inc (MNTA) Key Developments

Momenta Pharmaceuticals Inc. - Shareholder/Analyst Call

To discuss the approval of Glatopa (glatiramer acetate injection, formerly M356) 20mg/mL

Momenta Pharmaceuticals, Inc. Announces FAD Approval of ANDA for Glatopa(TM)

Momenta Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has granted marketing approval of Sandoz's Abbreviated New Drug Application for once daily Glatopa™ (glatiramer acetate injection, formerly M356) 20 mg/mL, a generic equivalent of daily COPAXONE® 20 mg. Glatopa is the first substitutable generic indicated for the treatment of patients with relapsing-forms of multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. Glatopa was developed under a collaboration agreement between Momenta and Sandoz and is the second complex generic developed by Momenta together with Sandoz to receive FDA approval. Glatopa will be commercialized under the Sandoz brand. Glatopa was determined by the FDA to be therapeutically equivalent to daily COPAXONE 20 mg, with the same active ingredients, route of administration, strength and dosage form. Glatopa's high quality U.S.-based supply chain and manufacturing process meets rigid FDA standards, and Glatopa is fully substitutable at the pharmacy level. Glatopa is expected to offer a more affordable treatment option for people living with RRMS. Under the terms of its collaboration agreement with Sandoz, Momenta is eligible to receive up to $140 million in milestone payments upon the achievement of certain U.S. regulatory, commercial and sales-based milestones for Glatopa, including a $10.0 million payment earned upon sole FDA approval of the ANDA, and another $10.0 million milestone payment upon first commercial sale.

Momenta Pharmaceuticals Announces Publication Revealing Development of a Novel Process to Generate High-Quality Hyper-Sialylated Ivig Drug Candidate in PNAS

Momenta Pharmaceuticals Inc. announced that results from preclinical studies on its hyper-sialylated IVIg (hsIVIg) program. The article summarizes Momenta's progress in creating a hsIVIg drug candidate with the potential for more consistent and enhanced anti-inflammatory activity compared to the current IVIg therapy used to treat inflammatory and autoimmune diseases. IVIg therapy has demonstrated beneficial therapeutic effects and is often used as a last line of defense in many severe inflammatory diseases. Although efficacious in these diseases, inconsistent efficacy and potency remain as major limitations for patients and physicians using IVIg. The identification of the important anti-inflammatory role of Fc-sialylation has presented the opportunity to develop a more potent alternative therapy to IVIg; however, translating this finding into a more potent anti-inflammatory product has been hampered by the difficulty of generating sialylated products suitable for clinical use. Momenta utilized its expertise in the characterization and engineering of complex biologics to develop a robust and scalable process to generate a hyper-sialylated IVIg drug candidate for potential clinical development.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MNTA:US $17.57 USD +0.49

MNTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amarin Corp PLC $2.33 USD -0.04
Natco Pharma Ltd 2,340 INR -34.30
OraSure Technologies Inc $6.52 USD -0.19
SciClone Pharmaceuticals Inc $8.88 USD +0.05
Sucampo Pharmaceuticals Inc $20.00 USD -0.24
View Industry Companies
 

Industry Analysis

MNTA

Industry Average

Valuation MNTA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 17.1x
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MOMENTA PHARMACEUTICALS INC, please visit www.momentapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.